Ronald B Goldberg1, Trevor J Orchard2, Jill P Crandall3, Edward J Boyko4, Matthew Budoff5, Dana Dabelea6, Kishore M Gadde7, William C Knowler8, Christine G Lee9, David M Nathan10, Karol Watson11, Marinella Temprosa12. 1. University of Miami Miller School of Medicine, FL (R.B.G.). 2. University of Pittsburgh Graduate School of Public Health, PA (T.J.O.). 3. Albert Einstein College of Medicine, Bronx, NY (J.P.C.). 4. VA Puget Sound Health Care System, Seattle, WA (E.J.B.). 5. Los Angeles Biomedical Research Institute, Torrance, CA (M.B.). 6. University of Colorado Anschutz Medical Campus, Aurora (D.D.). 7. Pennington Biomedical Research Center, Baton Rouge, LA (K.M.G.). 8. National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, AZ (W.C.K.). 9. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD (C.G.L.). 10. Massachusetts General Hospital, Harvard Medical School, Boston (D.M.N.). 11. David Geffen School of Medicine at UCLA, Los Angeles, CA (K.W.). 12. Biostatistics Center and Milken Institute School of Public Health, George Washington University, Rockville, MD (M.T.).
Abstract
BACKGROUND: Lifestyle intervention and metformin have been shown to prevent diabetes; however, their efficacy in preventing cardiovascular disease associated with the development of diabetes is unclear. We examined whether these interventions reduced the incidence of major cardiovascular events over a 21-year median follow-up of participants in the DPP trial (Diabetes Prevention Program) and DPPOS (Diabetes Prevention Program Outcomes Study). METHODS: During DPP, 3234 participants with impaired glucose tolerance were randomly assigned to metformin 850 mg twice daily, intensive lifestyle or placebo, and followed for 3 years. During the next 18-year average follow-up in DPPOS, all participants were offered a less intensive group lifestyle intervention, and unmasked metformin was continued in the metformin group. The primary outcome was the first occurrence of nonfatal myocardial infarction, stroke, or cardiovascular death adjudicated by standard criteria. An extended cardiovascular outcome included the primary outcome or hospitalization for heart failure or unstable angina, coronary or peripheral revascularization, coronary heart disease diagnosed by angiography, or silent myocardial infarction by ECG. ECGs and cardiovascular risk factors were measured annually. RESULTS: Neither metformin nor lifestyle intervention reduced the primary outcome: metformin versus placebo hazard ratio 1.03 (95% CI, 0.78-1.37; P = 0.81) and lifestyle versus placebo hazard ratio 1.14 (95% CI, 0.87-1.50; P = 0.34). Risk factor adjustment did not change these results. No effect of either intervention was seen on the extended cardiovascular outcome. CONCLUSIONS: Neither metformin nor lifestyle reduced major cardiovascular events in DPPOS over 21 years despite long-term prevention of diabetes. Provision of group lifestyle intervention to all, extensive out-of-study use of statin and antihypertensive agents, and reduction in the use of study metformin together with out-of-study metformin use over time may have diluted the effects of the interventions. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifiers: DPP (NCT00004992) and DPPOS (NCT00038727).
BACKGROUND: Lifestyle intervention and metformin have been shown to prevent diabetes; however, their efficacy in preventing cardiovascular disease associated with the development of diabetes is unclear. We examined whether these interventions reduced the incidence of major cardiovascular events over a 21-year median follow-up of participants in the DPP trial (Diabetes Prevention Program) and DPPOS (Diabetes Prevention Program Outcomes Study). METHODS: During DPP, 3234 participants with impaired glucose tolerance were randomly assigned to metformin 850 mg twice daily, intensive lifestyle or placebo, and followed for 3 years. During the next 18-year average follow-up in DPPOS, all participants were offered a less intensive group lifestyle intervention, and unmasked metformin was continued in the metformin group. The primary outcome was the first occurrence of nonfatal myocardial infarction, stroke, or cardiovascular death adjudicated by standard criteria. An extended cardiovascular outcome included the primary outcome or hospitalization for heart failure or unstable angina, coronary or peripheral revascularization, coronary heart disease diagnosed by angiography, or silent myocardial infarction by ECG. ECGs and cardiovascular risk factors were measured annually. RESULTS: Neither metformin nor lifestyle intervention reduced the primary outcome: metformin versus placebo hazard ratio 1.03 (95% CI, 0.78-1.37; P = 0.81) and lifestyle versus placebo hazard ratio 1.14 (95% CI, 0.87-1.50; P = 0.34). Risk factor adjustment did not change these results. No effect of either intervention was seen on the extended cardiovascular outcome. CONCLUSIONS: Neither metformin nor lifestyle reduced major cardiovascular events in DPPOS over 21 years despite long-term prevention of diabetes. Provision of group lifestyle intervention to all, extensive out-of-study use of statin and antihypertensive agents, and reduction in the use of study metformin together with out-of-study metformin use over time may have diluted the effects of the interventions. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifiers: DPP (NCT00004992) and DPPOS (NCT00038727).
Entities:
Keywords:
cardiovascular diseases; diabetes mellitus, type 2; metformin
Authors: J David Curb; Anne McTiernan; Susan R Heckbert; Charles Kooperberg; Janet Stanford; Michael Nevitt; Karen C Johnson; Lori Proulx-Burns; Lisa Pastore; Michael Criqui; Sandra Daugherty Journal: Ann Epidemiol Date: 2003-10 Impact factor: 3.797
Authors: Karen A Hicks; James E Tcheng; Biykem Bozkurt; Bernard R Chaitman; Donald E Cutlip; Andrew Farb; Gregg C Fonarow; Jeffrey P Jacobs; Michael R Jaff; Judith H Lichtman; Marian C Limacher; Kenneth W Mahaffey; Roxana Mehran; Steven E Nissen; Eric E Smith; Shari L Targum Journal: J Am Coll Cardiol Date: 2014-12-29 Impact factor: 24.094
Authors: Rodney A Hayward; Peter D Reaven; Wyndy L Wiitala; Gideon D Bahn; Domenic J Reda; Ling Ge; Madeline McCarren; William C Duckworth; Nicholas V Emanuele Journal: N Engl J Med Date: 2015-06-04 Impact factor: 91.245
Authors: Hertzel C Gerstein; Michael E Miller; Robert P Byington; David C Goff; J Thomas Bigger; John B Buse; William C Cushman; Saul Genuth; Faramarz Ismail-Beigi; Richard H Grimm; Jeffrey L Probstfield; Denise G Simons-Morton; William T Friedewald Journal: N Engl J Med Date: 2008-06-06 Impact factor: 91.245
Authors: Yali An; Ping Zhang; Jinping Wang; Qiuhong Gong; Edward W Gregg; Wenying Yang; Hui Li; Bo Zhang; Ying Shuai; Yanyan Chen; Michael M Engelgau; Yiling Cheng; Yinghua Hu; Peter H Bennett; Guangwei Li Journal: Diabetes Care Date: 2015-04-17 Impact factor: 19.112
Authors: Matti Uusitupa; Markku Peltonen; Jaana Lindström; Sirkka Aunola; Pirjo Ilanne-Parikka; Sirkka Keinänen-Kiukaanniemi; Timo T Valle; Johan G Eriksson; Jaakko Tuomilehto Journal: PLoS One Date: 2009-05-21 Impact factor: 3.240